Evaluation of the Reconstruction Parameters of Brain Dopamine Transporter SPECT Images Obtained by a Fan Beam Collimator: A Comparison with Parallel-hole Collimators

Document Type: Original Article


1 Division of Medical Quantum Science, Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

2 Radiological Science Course, Department of Health Sciences, School of Medicine, Kyushu University, Fukuoka, Japan

3 Division of Radiology, Department of Medical Technology, Kyushu University Hospital, Fukuoka, Japan

4 Department of Clinical Radiology, Kyushu University Hospital, Fukuoka, Japan


Objective(s): The purpose of this study was to examine the optimal reconstruction parameters for brain dopamine transporter SPECT images obtained with a fan beam collimator and compare the results with those obtained by using parallel-hole collimators.
Methods: Data acquisition was performed using two SPECT/CT devices, namely a Symbia T6 and an Infinia Hawkeye 4 (device A and B) equipped with fan-beam (camera A-1 and B-1), low- and medium-energy general-purpose (camera A-2 and B-2), and low-energy high-resolution (camera A-3 and B-3) collimators. The SPECT images were reconstructed using filtered back projection (FBP) with Chang’s
attenuation correction. However, the scatter correction was not performed. A pool phantom and a three-dimensional (3D) brain phantom were filled with 123I solution to examine the reconstruction parameters. The optimal attenuation coefficient was based on the visual assessment of the profile curve, coefficient of variation (CV) [%], and summed difference from the reference activity of the pool phantom. The optimal Butterworth filter for the 3D-brain phantom was also determined based on a visual assessment. The anthropomorphic striatal phantom was filled with 123I solution at striatum-to-background radioactivity ratios of 8, 6, 4, and 3. The specific binding ratio (SBR) of the striatum (calculated by the CT method) was used to compare the results with those of the parallel-hole collimators.
Results: The optimal attenuation coefficients were 0.09, 0.11, 0.05, 0.05, 0.11, and, 0.10 cm-1 for cameras A-1, A-2, A-3, B-1, B-2, and B-3, respectively. The cutoff frequencies of the Butterworth filter were 0.32, 0.40, and 0.36 cycles/cm for camera A, and 0.46, 0.44, and 0.44 cycles/cm for camera B, respectively. The recovery rates of the SBRmean with camera A were 51.2%, 49.4%, and 45.6%, respectively. The difference was not
statistically significant. The recovery rates of the SBR with camera B were 59.2%, 50.7%, and 50.8%, respectively. Camera B-1 showed significantly high SBR values.
Conclusion: As the findings indicated, the optimal reconstruction parameters differed according to the devices and collimators. The fan beam collimator was found to provide promising results with each device.


Main Subjects

  1. Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53(1):154-63.
  2. Darcourt J, Booji J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37(2):443-50.
  3. O’Sullivan JD, Lees AJ. Nonparkinsonian tremors. Clin Neuropharmacol. 2000;23(5):233-8.
  4. Furukawa Y, Kish SJ. Dopa-responsive dystonia: recent advances and remaining issues to be addressed. Mov Disord. 1999;14(5):709-15.
  5. Albanece A, Colosimo C, Lees AJ, Tonali P. The clinical diagnosis of multiple system atrophy presenting as pure Parkinsonism. Adv Neurol. 1996;69:393-8.
  6. Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]-FP-CIT SPET in healthy volunteers. Eur J Nucl Med Mol Imaging. 2000;27(7):867-9.
  7. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, et al. Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry. 1986;49(8):853-60.
  8. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson’s disease. Arch Neurol. 1990;47(12):1290-8.
  9. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT- FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1996;37(11):1760-5.
10. Eshuis SA, Maguire RP, Leender KL, Jonkman S, Jager PL. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2006;33(2):200-9.

11. Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2009;36(3):454-62.

12. Maebatake A, Sato M, Kagami R, Yamashita Y, Komiya I, Himuro K. et al. An anthropomorphic phantom study of brain dopamine transporter SPECT images obtained using different SPECT/CT devices and collimators. J Nucl Med Technol. 2015;43(1):41-6.

13. Maebatake A, Imamura A, Kodera Y, Yamashita Y, Himuro K, Baba S, et al. Evaluation of iterative reconstruction method and attenuation correction in brain dopamine transporter SPECT using an anthropomorphic striatal phantom. Asia Ocean J Nucl Med Biol. 2016;4(2):72-80.

14. Tsui BM, Gullberg GT, Edgerton ER, Gilland DR, Perry JR, McCartney WH. Design and clinical utility of a fan beam collimator for SPECT imaging of the head. J Nucl Med. 1986;27(6):810-9.

15. Kouris K, Clarke GA, Jarrit PH, Townsend CE, Thomas SN. Physical performance evaluation of the Toshiba GCA-9300A triple-headed. J Nucl Med. 1993;34(10):1778-89.

16. King MA, Mukherjee JM, KÓ§nik A, Zubal IG, Dey J, Licho R. Design of a multi-pinhole collimator for I-123 DaTscan Imaging on dual-headed SPECT systems in combination with a fan-beam collimator. IEEE Trans Nucl Sci. 2016;63(1):90-7.

17. Iida H, Hori Y, Ishida K, Imabayashi E, Matsuda H, Takahashi M, et al. Three-dimensional brain phantom containing bone and grey matter structures with a realistic head contour. Ann Nucl Med. 2013;27(1):25-36.

18. Snay ER, Treves ST, Fahey FH. Improved quality of pediatric 123I-MIBG images with medium-energy collimators. J Nucl Med Technol. 2011;39(2):100-4.

19. Verberne HJ, Feenstra C, de Jong WM, Somsen GA, van Eck-Smit BL, Busemann Sokole E. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging. 2005;32(9):1100-7.

20. Crespo C, Gallego J, Cot A, Falcón C, Bullich S, Pareto D, et al. Quantification of dopaminergic neurotransmission SPECT studies with 123I-labelled radioligands. A comparison between different imaging systems and data acquisition protocols using Monte Carlo simulation. Eur J Nucl Med Mol Imaging. 2008;35(7):1334-42.

21. Frouin V, Comtat C, Reilhac A, Grégoire MC. Correction of partial-volume effect for PET striatal imaging: fast implementation and study of robustness. J Nucl Med. 2002;43(12):1715-26.

22. Soret M, Koulibaly PM, Darcourt J, Hapdey S, Buvat I. Quantitative accuracy of dopaminergic neurotransmission imaging with 123I SPECT. J Nucl Med. 2003;44(7):1184-93.

23. Buvat I, Soret M, Hapdey S, Riddell C, Benali H, Di Paola R. Respective importance of scatter, attenuation, collimator response and partial volume effect corrections for accurate quantification in 123I dopamine receptor imaging. IEEE Med Imaging Conf Record. 2000;2:13-5.

24. Soret M, Koulibaly PM, Darcourt J, Buvat I. Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative disease: impact upon patient classification. Eur J Nucl Med Mol Imaging. 2006;33(9):1062-72.

25. Tossici-Bolt L, Hoffman SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006;33(12):1491-9.

26. Cot A, Falcón C, Crespo C, Sempau J, Pareto D, Bullich S, et al. Absolute quantification in dopaminergic neurotransmission SPECT using a Monte Carlo-based scatter correction and fully 3-dimensional reconstruction. J Nucl Med. 2005;46(9):1497-504.